administration via distal-release pellets	placebo	concentrations of the final catabolic product of ATP, uric acid	1641	1916	concentrations of the final catabolic product of ATP, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and naso-duodenal tube (P = 0.001), but not after administration via distal-release pellets
administration via proximal-release pellets	placebo	concentrations of the final catabolic product of ATP, uric acid	1639	1824	, concentrations of the final catabolic product of ATP, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003)
administration via proximal-release pellets	administration via distal-release pellets	increase in plasma lithium	21591	21799	Comparison of the AUC of the two types of ATP-containing pellets revealed that the proximal-release pellets caused a significantly higher increase in plasma lithium than the distal-release pellets (P = 0.001)
administration via proximal-release pellets	administration via distal-release pellets	increase in plasma lithium	21591	21811	Comparison of the AUC of the two types of ATP-containing pellets revealed that the proximal-release pellets caused a significantly higher increase in plasma lithium than the distal-release pellets (P = 0.001) (Figure 3).
administration via naso-duodenal tube	placebo	concentrations of the final catabolic product of ATP, uric acid	1641	1916	concentrations of the final catabolic product of ATP, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and naso-duodenal tube (P = 0.001), but not after administration via distal-release pellets
administration via proximal-release pellets	placebo	concentrations of the final catabolic product of ATP, uric acid	1641	1916	concentrations of the final catabolic product of ATP, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and naso-duodenal tube (P = 0.001), but not after administration via distal-release pellets
administration via naso-duodenal tube	placebo	concentrations of the final catabolic product of ATP, uric acid	1641	1860	concentrations of the final catabolic product of ATP, uric acid, were significantly increased compared to placebo by ~50% after administration via proximal-release pellets (P = 0.003) and naso-duodenal tube (P = 0.001),
